Related references
Note: Only part of the references are listed.Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Adalimumab for the treatment of fistulas in patients with Crohn's disease
J-F Colombel et al.
GUT (2009)
Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults
J. Lindsay et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker
S. Danese
DIGESTIVE AND LIVER DISEASE (2008)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study
Brian G. Feagan et al.
GASTROENTEROLOGY (2008)
Leukocyte Adhesion Molecules in Animal Models of Inflammatory Bowel Disease
Jesus Rivera-Nieves et al.
INFLAMMATORY BOWEL DISEASES (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Resource use in patients with Crohn's disease treated with infliximab
C. Saro et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006
M. Clark et al.
GASTROENTEROLOGY (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Safety of biologic therapy
Wojciech Blonski et al.
INFLAMMATORY BOWEL DISEASES (2007)
Immune regulation by microvascular endothelial cells: Directing innate and adaptive immunity, coagulation, and inflammation
Silvio Danese et al.
JOURNAL OF IMMUNOLOGY (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
The fundamental basis of inflammatory bowel disease
Warren Strober et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
Ann Corken Mackey et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2007)
The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients
Lene Riis et al.
INFLAMMATORY BOWEL DISEASES (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Corticosteroid therapy in the age of infliximab: Acute and 1-year outcomes in newly diagnosed children with Crohn's disease
James Markowitz et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn's disease
W. Reinisch et al.
GUT (2006)
Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
D. W. Hommes et al.
GUT (2006)
Predictors of Crohn's disease
L Beaugerie et al.
GASTROENTEROLOGY (2006)
TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation:: A novel anti-inflammatory mechanism of infliximab in Crohn's disease
S Danese et al.
JOURNAL OF IMMUNOLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Serum immune responses predict rapid disease progression among children with Crohn's disease: Immune responses predict disease progression
MC Dubinsky et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation
S Danese et al.
DIGESTIVE AND LIVER DISEASE (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease
DSA Sanders
JOURNAL OF CLINICAL PATHOLOGY (2005)
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
GR Lichtenstein et al.
GASTROENTEROLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Anti-interleukin-12 antibody for active Crohn's disease
PJ Mannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo
C Brunner et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
